REGIS NU643 Week 6 Quiz Latest 2021 January (100% Graded)

Week 6 Quiz

Question 1Match the following classes of antidepressant to their unique characteristics.

Selective Serotonin Reuptake Inhibitors                Answer 1 

Tricyclic Antidepressants (TCAs)                Answer 2 

Monoamine Oxidase Inhibitors Answer 3 

Question 2Match the following SSRIs to their unique clinical profile.

Paroxetine         

Fluvoxamine     

Citalopram         

Sertraline           

Escitalopram     

Fluoxetine         

Question 3Dry mouth from antidepressants:

 a.will likely resolve with time.

 b.can lead to increased risk of dental caries.

 c.is best treated with a beta blocker.

 d.is best treated with an anticholinergic medication.

Question 4Independent of antidepressant use, depression is thought to cause which symptom of sexual dysfunction?

 a.Low libido

 b.Anorgasmia

 c.Delayed ejaculation

 d.None of the above

Question 5The monoamine transporters SERT (serotonin), NET (norepinephrine) and DAT (dopamine) are key targets for most of the known:

 a.Anxiolytics

 b.Antidepressants

 c.Anticonvulsants

 d.Antipsychotics

Question 6When a patient achieves remission of depression, what is the recommended length of time that treatment should continue?

 a.The recommended length of treatment depends on the number of depressive episodes that a patient has had.

 b.A patient should continue treatment for a minimum of 6 months.

 c.A patient should continue treatment for a minimum of 1 year.

 d.A patient should continue treatment indefinitely.

Question 7When comparing serotonin syndrome to hypertensive crisis, which of the follow statements is true?

 a.Hypertension is the hallmark symptom of hypertensive crisis; serotonin syndrome is marked by hypotension.

 b.Hypertensive crisis requires emergency care; serotonin syndrome can be managed outpatient and usually resolves without intervention.

 c.While both syndromes have muscular symptoms, only serotonin syndrome has hyperreflexia and myoclonus.

 d.Hypertensive crisis is associated with ataxia and incoordination; there are no gait disturbances in serotonin syndrome.

Question 8When treating a depressed patient who is treatment resistant, which of the following factors are important to consider?

 a.Patients who do not respond or remiss are usually non-adherent.

 b.Misdiagnosis should be considered as a factor in non- or partial responders.

 c.Clinician attitude is irrelevant to outcome.

 d.A patient who has not responded to four treatment trials is unlikely to respond to further trials.

Question 9 Which antidepressant is least likely to cause sexual side effects?

 a.Paroxetine

 b.Fluoxetine

 c.Bupropion

 d.Sertraline

Question 10 Which of the follow is true about repetitive Transcranial Magnetic Stimulation (rTMS)?

 a.rTMS is not yet FDA approved for treatment of depression.

 b.rTMS treatment requires anesthesia.

 c.rTMS has the side effect of memory loss.

d.Standard rTMS treatments occur once a weekday for six weeks.

Question 11Which of the follow statements is true about antidepressant side effects?

 a.Side effects rarely resolve on their own.

 b.The most common side effects are also the most bothersome to patients.

 c.Discussing possible side effects before starting medication is associated with patients staying on medications longer.

 d.Patients are likely to self-report side effects.

Question 12Which of the follow statements is true about dietary tyramine and MAO inhibitors?

 a.Tyramine is metabolized by monoamine oxidase.

 b.Tyramine levels lower in the presence of MAO Inhibitors.

 c.Low tyramine levels are associated with hypotensive crisis.

 d.Tyramine is naturally occurring in most carbohydrates.

Question 13Which of the following agents is considered to have the best evidence as an augmentation agent in the treatment of depression?

 a.Bupropion

b.Lithium

 c.Methylphenidate

 d.Haloperidol

Question 14Which of the following antidepressant side effects may resolve with time?

 a.Sexual side effects

 b.Agitation

 c.Weight gain

 d.Apathy

Question 15Which of the following describes treatment resistance?

 a.Patient forgets to take their medication and fails to respond to treatment.

 b.A patient takes a medication that lowers the blood levels of their antidepressant and fails to respond to treatment.

 c.A patient has two adequate trials of antidepressants and fails to respond to treatment.

 d.A patient has an adverse response to an antidepressant.

Question 16Which of the following foods would be considered safe when consumed concurrently with a monoamine oxidase inhibitor?

 a.A pint of craft beer.

 b.A platter of aged cheese and cured meat.

 c.A bowl of ice cream.

 d.A ham sandwich.

Question 17 Which of the following is hypothesized to be true about neural circuits in depression?

 a.Neural circuits have little effect on depression presentation.

 b.Depression is due to dysfunction in a single depression neural circuit.

 c.Monoamine neurotransmitters have equal effect in each brain circuit.

 d.Neural circuits are hypothesized to account for variability in depression presentation.

Question 18Which of the following is true about antidepressant treatment?

 a.Most patients achieve remission on their first antidepressant treatment.

 b.Concentration and motivation are mostly likely to respond to antidepressant treatment.

c.Patients that achieve remission are less likely to relapse.

 d.Patients should discontinued medication as soon as remission is achieved.

Question 19Which of the following is true about antidepressants and bleeding?

 a.Serotonin reuptake inhibition increases serotonin in the platelets.

b.Bleeding is a common adverse side effect of antidepressant treatment.

 c.All antidepressants can cause bleeding.

 d.Concurrent use of antidepressants and NSAIDS can increase risk of bleeding.

Question 20Which of the following is true about electroconvulsive therapy (ECT)?

 a.ECT a first-line treatment for depression.

 b.ECT is a cost-effective treatment for depression.

c.ECT has a rapid onset of action for depression.

 d.Side effects of ECT are minimal and not life-disruptive.

Question 21Which of the following is true about hyponatremia and antidepressants?

 a.Hyponatremia is common throughout the course of antidepressant treatment.

 b.Symptoms of hyponatremia include lethargy, delirium, and nausea.

 c.Once present, hyponatremia is unlikely to resolve.

 d.Hyponatremia occurs with equal incidence across the lifespan.

Question 22Which of the following is true about tricyclic antidepressants?

 a.They are not considered effective agents for depression.

 b.They have histaminergic side effects of weight gain and sedation.

 c.They have potential to cause hypertensive crisis at higher doses.

d.They are considered safe in overdose.

Question 23Which of the following is true when comparing desvenlafaxine to venlafaxine?

 a.Desvenlafaxine is the generic name for venlafaxine.

 b.Desvenlafaxine's safety profile is proven to be superior to venlafaxine.

c.Desvenlafaxine likely no more efficacious venlafaxine.

 d.Desvenlafaxine is priced similarly to venlafaxine.

Question 24Which of the following neurotransmitters is not considered significant in mood disorders?

 a.Acetylcholine

 b.Serotonin

 c.Dopamine

 d.Norepinephrine

Question 25Which of the following statements about antidepressant augmentation with atypical antipsychotics is true?

 a.There is no evidence supporting the use of atypical antipsychotics as an augmentation strategy.

 b.Atypical antipsychotics are superior to other agents as an augmentation strategy.

 c.As a class, atypical antipsychotics are equally effective as an augmentation strategy in depression.

 d.Risks of atypical antipsychotics (metabolic issues, EPS) should be considered before prescribing as an augmentation strategy.

Question 26Which of the following statements about bupropion is true?

 a.Bupropion may have a mild benefit in ADHD.

 b.Bupropion is contraindicated in patients who smoke nicotine.

 c.Bupropion can raise the seizure threshold and is safe in patients with a seizure history.

 d.Antidepressant effects of bupropion are due to serotonin reuptake inhibition.

Question 27Which of the following statements about psychotherapy in the treatment of depression is true?

 a.Few types of psychotherapy create epigenetic changes in the brain.

 b.Psychotherapy can work synergistically with psychotropic medication.

 c.CBT has poor evidence as an adjunctive treatment for depression.

 d.Evidence for psychotherapy in depression is limited to mild depression.

Question 28Which of the following statements about stress and depression is true?

 a.Increased BDNF leads to the depletion of monoamine neurotransmitters.

b.BDNF is dysregulated in stress.

 c.Neuronal loss in depression is irreversible.

 d.Prolonged stress in early childhood is irrelevant to resilience in later life stress.

Question 29Which of the following statements about the STAR*D study is true?

 a.STAR*D was a large randomized, placebo-controlled study examining best treatments for depression.

 b.STAR*D found that 50% of patients achieve remission with monotherapy antidepressant.

c.STAR*D findings suggest that antidepressant non-responders should be switched to a different medication, whereas partial responders should be augmented.

 d.STAR*D found that lithium augmentation was superior to bupropion in partial responders.

Question 30Which of the following statements best describes the mechanism of action of selective serotonin reuptake inhibitors?

 a.SSRIs decrease serotonin levels at the synaptic cleft.

 b.SSRIs increase serotonin reuptake at the presynaptic neuron.

c.SSRIs cause the indirect downregulation of 5HT1A autoreceptors, increasing neuronal impulse flow.

 d.SSRIs increase dopamine reuptake at the postsynaptic neuron.

Question 31Which of the following statements is true about duloxetine?

 a.Duloxetine is a selective serotonin reuptake inhibitor (SSRI).

 b.Duloxetine is FDA approved for the treatment of migraines.

 c.Duloxetine carries risks for liver toxicity and should be avoided in patients with liver disease.

 d.Duloxetine is available as a generic medication and is an affordable option for most patients.

Question 32Which of the following statements is true about mirtazapine?

 a.Mirtazapine is classified as a serotonin and norepinephrine reuptake inhibitor (SNRI).

 b.Mirtazapine is a poor choice for patients with comorbid anxiety.

 c.Mirtazapine has side effects of weight gain and sedation.

 d.Mirtazapine would be a good choice for patients with an anergic presentation.

Question 33Which of the following statements is true about suicide and antidepressant use?

 a.Antidepressant use lowers the incidence of suicide in patients over 65.

 b.Antidepressant use increases incidence of completed suicides in young adults (ages 18-24).

 c.The incidence of suicide in young adults on antidepressants is statistically significant.

 d.There is no correlation between antidepressant use and suicidality.

Question 34Which of the following statements is true about trazodone?

 a.Trazodone has a long half-life.

 b.Trazodone is an effective hypnotic at low doses.

 c.Trazodone is an effective antidepressant.

d.Trazodone should not be used in combination with other antidepressants.

Question 35Which of the following statements is true about venlafaxine?

 a.Venlafaxine is a selective serotonin reuptake inhibitor.

b.Venlafaxine can cause hypertension at higher doses.

 c.Venlafaxine should be considered as a medication choice for patients who forget to take medication.

 d.Venlafaxine is the generic formulation of desvenlafaxine.

Question 36Which of the following statements most accurately describes the monoamine receptor hypothesis of depression?

 a.The monoamine receptor hypothesis posits that deficiencies in monoamines are the cause of depression.

b.The monoamine receptor hypothesis posits that dysregulation of monoamine receptors alters molecular events such as gene expression.

 c.The monoamine receptor hypothesis is well-supported by research and clinical evidence.

 d.The monoamine receptor hypothesis has been proven false by research and clinical evidence.